Treatment of Relapsed or Refractory Acute Leukemia: Comparison of Two Different Regimens
- 1 January 1990
- book chapter
- Published by Springer Nature
- Vol. 33, 614-618
- https://doi.org/10.1007/978-3-642-74643-7_112
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.Journal of Clinical Oncology, 1987
- Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.Journal of Clinical Oncology, 1986
- High-Dose Cytosine-Arabinoside and Mitoxantrone in Refractory Acute Myeloid Leukemia: A Clinical Phase I/II-StudyOncology Research and Treatment, 1986
- Phase I study of VP‐16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemiaMedical and Pediatric Oncology, 1985
- High-dose cytosine arabinoside therapy for refractory leukemiaBlood, 1983
- Reporting results of cancer treatmentCancer, 1981